Previous 10 | Next 10 |
To further consolidate its position in molecular diagnostics, Roche Holding (OTCQX:RHHBY) (OTCQX:RHHBF) has agreed to acquire German-based biotech company TIB Molbiol Group. On Thursday, Roche announced a definitive share purchase agreement to acquire 100% of outstanding shares of T...
It might have been a mixed day for the broader averages, but AMC Entertainment (NYSE:AMC) had an unambiguously good session. No, this wasn't a result of meme-stock traders attempting to force another short squeeze -- at least, not completely. Rather, AMC shares reacted to actual positive...
FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “Adaptimmune Therapeutics plc on the Rise After Entering into a Strategic Collaboration with Genentech” Adaptimmune Therapeutics (NASDAQ: ADAP) plc climbed over 23%...
Shares of the clinical-stage biotech Adaptimmune Therapeutics (NASDAQ: ADAP) popped by as much as 25% in premarket trading Tuesday morning. The cancer specialist's stock is on the move this morning in response to a licensing and collaboration agreement with Roche 's (OTC: RHHB...
- Combining both companies’ cell therapy leadership and expertise, the collaboration covers the research and development of “off-the-shelf” cell therapies for up to five shared cancer targets and the development of a novel allogeneic personalized cell therapy platform -...
- One complete response, and a disease control rate of 64% with stable disease for ≥16 weeks in two patients, as of the data cutoff - - Data presented today at the International Liver Cancer Association meeting at 12:25 p.m. CET - PHILADELPHIA and OXFORDSHIRE, United Kingdom,...
You can read full article here. For further details see: Wall Street Breakfast: The Week Ahead (Podcast)
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. Economic reports in the week ahead The latest trading week of the slower season could be an active one. Economic reports out include updates on pending hom...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha, Apple Po...
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...
News, Short Squeeze, Breakout and More Instantly...
Adaptimmune Therapeutics plc Company Name:
ADAP Stock Symbol:
NASDAQ Market:
Adaptimmune Therapeutics plc Website:
Approved for advanced MAGE-A4+synovial sarcoma in adults with certain HLA types who have received prior chemotherapy TECELRA is the first new treatment option for people with synovial sarcoma in more than a decade Adaptimmune to hold webcast at https://www.gowebcasti...
2024-07-30 07:30:03 ET H.C. Wainwright analyst issues BUY recommendation for ADAP on July 30, 2024 06:07AM ET. ADAP was trading at $1.37 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 4 - Buy, 1 - Hold, ...
2024-07-30 07:00:10 ET Arthur He from H.C. Wainwright issued a price target of $4.00 for ADAP on 2024-07-30 06:07:00. The adjusted price target was set to $4.00. At the time of the announcement, ADAP was trading at $1.37. The overall price target consensus is at $2.54 wi...